Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women

Journal of Clinical Endocrinology and Metabolism

Volumn 86, Issue 3, 2001, Pages 1116-1125

  Murphy, M G ^a   Weiss, S ^b   McClung, M ^c   Schnitzer, T ^d,e   Cerchio, K ^a   Connor, J ^a   Krupa, D ^a   Gertz, B J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b San Diego Endocrine and Medical Clinic   (United States)

^c OREGON OSTEOPOROSIS CENTER   (United States)

^d RUSH UNIVERSITY MEDICAL CENTER   (United States)

^e Northwestern Center for Clinical Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE BONE ISOENZYME; CALCIUM; GROWTH HORMONE; IBUTAMOREN; OSTEOCALCIN; PLACEBO; SOMATOMEDIN C;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE MASS; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FEMUR NECK; FRACTURE; GROWTH HORMONE RELEASE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OSSIFICATION; OSTEOBLAST; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

AGED; ALENDRONATE; ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; BONE REMODELING; COLLAGEN; COLLAGEN TYPE I; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMAN GROWTH HORMONE; HUMANS; INDOLES; INSULIN-LIKE GROWTH FACTOR I; MIDDLE AGED; OSTEOCALCIN; OSTEOPOROSIS, POSTMENOPAUSAL; PEPTIDES; PLACEBOS; SPIRO COMPOUNDS; TIME FACTORS;

EID: 0035044615     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.86.3.1116     Document Type: Article

References (44)

1. The prevention and treatment of osteoporosis
2. Appendicular bone mineral and a woman's lifetime risk of hip fracture
3. Prevalence and incidence of vertebral deformities
4. Long-term prevention of postmenopausal osteoporosis by oestrogen: Evidence for an increased bone mass after delayed onset of oestrogen treatment
5. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis
6. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
7. Quantitative measurements of periosteal and cortical-endosteal bone formation and resorption in the mid-shaft of male rat femur
8. Insulin-like growth factor II and transforming growth factor β regulate collagen expression in human osteoblastlike cell in vitro
9. Growth hormone stimulates bone formation and strength of cortical bone in aged rats
10. Effects of sex and age on the 24-hour profile of growth hormone secretion in man: Importance of endogenous estradiol concentrations
11. Neuroendocrine rhythms and sleep in aging men
12. Differential impact of age, sex steroid hormones and obesity on basal versus pulsatile growth hormone secretion in men as assessed in an ultrasensitive chemiluminescent assay
13. Human growth hormone and human aging
14. Effects of recombinant insulin-like growth factor-I and growth hormone on bone turnover in elderly women
15. Effects of recombinant human growth hormone on metabolic indices, body composition, and bone turnover in healthy elderly women
16. Effects of short-term administration of recombinant human growth hormone to elderly people
17. Growth hormone treatment of adults with growth hormone deficiency; a result of a 13-month placebo-controlled cross-over study
18. Short-term treatment with growth hormone stimulates osteoblastic and osteoclastic activity in osteopenic postmenopausal women: A dose-response study
19. Effect of GH on biochemical markers of bone turnover in postmenopausal osteoporotic women
20. The effect of growth hormone (GH) on histomorphometric indices of bone structure and bone turnover in GH-deficient men
21. Effect of growth hormone replacement on bone mass in adult onset growth hormone deficiency
22. Two years of growth hormone (GH) increases bone mineral content and density in hypopituitary patients with adult-onset GH deficiency
23. The effects of prolonged growth hormone replacement on bone metabolism and bone mineral density in hypopituitary adults
24. Effects of human growth hormone in men over 60 years old
25. Growth hormone replacement in healthy older men improves body composition but not functional ability
26. The RIGHT study: A randomized placebo controlled trial of recombinant human growth hormone in frail elderly: Dose response effects on bone mass and bone turnover
27. Design and biological activities of L-163,191 (MK-0677): A potent, orally active growth hormone secretagogue
28. The growth hormone-releasing activity of a synthetic hexapeptide in normal men and short statured children after oral administration
29. Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone
30. Effect of a new synthetic hexapeptide to selectively stimulate growth hormone release in healthy human subjects
31. Modulation of pulsatile GH release through a novel receptor in hypothalamus and pituitary gland
32. Effects of a 7-day treatment with a novel, orally active, growth hormone (GH) secretagogue, MK-677, on 24-hour GH profiles, insulin-like growth factor I and adrenocortical function in normal young men
33. Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretagogue (MK-677) in healthy elderly subjects
34. Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults
35. Preclinical pharmacology of alendronate
36. The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates
37. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis
38. Oral alendronate induced progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis
39. Alendronate treatment of the postmenopausal osteoporotic woman: Effect of multiple dosages on bone mass and bone remodeling
40. Bisphosphonates: Mechanisms of action
41. Use of MK-677, an oral growth hormone secretagogue, in frail elderly subjects
42. Treatment of postmenopausal osteoporosis with a combination of growth hormone and pamidronate: A placebo-controlled trial
43. Combined treatment of growth hormone and the bisphosphonate pamidronate, versus treatment with GH alone, in GH-deficient adults: The effects on renal phosphate handling, bone turnover and bone mineral mass
44. Skeletal effects of cyclic recombinant human growth hormone and salmon calcitonin in osteopernic postmenopausal women